Home › Trial NCT05137860
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
- Trial IDNCT05137860
- StatusUnknown
- PhasePhase 4
- Study typeInterventional
- SponsorHospital General de Mexico
- Enrollment56
- Start date2021-12-12
- ConditionsAcute Lymphoblastic Leukemia, in Relapse · Chemotherapeutic Toxicity · Minimal Residual Disease
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.